In this randomized controlled trial, among patients with persistent chylomicronemia, it was found that plozasiran more ...

Privately-held Chinese firm Visirna Therapeutics has announced that a Phase III trial of VSA001 (plozasiran) has met both its ...

The company highlighted three primary growth drivers: plozasiran, obesity programs, and the emerging CNS pipeline. Plozasiran’s first commercial launch is anticipated by late 2025, pending FDA ...

The US Food and Drug Administration (FDA) has accepted a new drug application (NDA) for Arrowhead Pharmaceutical’s plozasiran in the same indication, a month after the first treatment was ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released topline results from Part 2 of a Phase 1/2 study of ARO-C3, the ...

With its lead candidate plozasiran nearing potential approval and a strategic shift towards cardiometabolic diseases, ARWR has captured the attention of investors and analysts alike. This ...

Phase 3 studies of plozasiran in severe hypertriglyceridemia are on pace to be fully enrolled in 2025 with potential study completion in 2026. We see emerging high-value potential in our obesity ...

"During the recent period, Arrowhead signed and closed a potentially transformational licensing and collaboration agreement with Sarepta Therapeutics and submitted our first NDA for investigational ...

Phase 3 studies of plozasiran in severe hypertriglyceridemia are on pace to be fully enrolled in 2025 with potential study completion in 2026. We see emerging high-value potential in our obesity ...

With its lead candidate plozasiran nearing potential approval and a strategic shift towards cardiometabolic diseases, ARWR has captured the attention of investors and analysts alike. This ...